AVLN insider filings

Avalyn Pharma Inc. — 21 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen AVLN transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 7 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
FMR LLC — 10% owner1—4 legs · 228,454 sh · $6,701,004—
Baranowski Lyn — Chief Executive Officer, Director1—5 legs · 52,500 sh · $1,461,4574
Carlson Douglas R — See Remarks1—3 legs · 14,875 sh · $414,9832
Rhodes Melissa — Chief Operating Officer1—3 legs · 13,300 sh · $371,0462
Lazarus Howard — Chief Medical Officer1—3 legs · 13,300 sh · $371,0272
Meyer Robert J. — Director2——1

Recent insider filings — Avalyn Pharma Inc.

FiledFormInsiderReported transactionsSource
2026-11-194Lazarus Howard — Chief Medical OfficerOption exercise (M): 13,300 @ $4.62 · Sale (S): 11,023 @ $27.80 · Sale (S): 2,066 @ $28.27 · Sale (S): 211 @ $29.27 · Option exercise (M): 13,300 (derivative) @ $0EDGAR
2026-11-194Carlson Douglas R — See RemarksOption exercise (M): 14,875 @ $4.62 · Sale (S): 11,527 @ $27.78 · Sale (S): 3,093 @ $28.22 · Sale (S): 255 @ $29.23 · Option exercise (M): 14,875 (derivative) @ $0EDGAR
2026-11-194Rhodes Melissa — Chief Operating OfficerOption exercise (M): 13,300 @ $4.62 · Sale (S): 10,875 @ $27.79 · Sale (S): 2,025 @ $28.21 · Sale (S): 400 @ $29.23 · Option exercise (M): 13,300 (derivative) @ $0EDGAR
2026-11-194Baranowski Lyn — Chief Executive Officer, DirectorOption exercise (M): 45,300 @ $4.62 · Sale (S): 39,600 @ $27.76 · Sale (S): 5,300 @ $28.15 · Sale (S): 400 @ $29.22 · Option exercise (M): 7,200 @ $4.62 · Sale (S): 6,465 @ $27.90 · +3 moreEDGAR
2026-11-124FMR LLC — 10% ownerSale (S): 173,661 @ $29.06 · Sale (S): 1,339 @ $29.75 · Sale (S): 5,565 @ $29.56 · Sale (S): 47,889 @ $30.28EDGAR
2026-09-173Meyer Robert J. — DirectorHoldings only — no transactions reportedEDGAR
2026-09-174Meyer Robert J. — DirectorGrant/award (A): 31,182 (derivative) @ $0EDGAR
2026-05-054FMR LLC — 10% ownerConversion (C): 727,585 · Conversion (C): 80,291 · Conversion (C): 872,868 · Conversion (C): 225,843 · Conversion (C): 377,948 · Conversion (C): 727,585 (derivative) · +4 moreEDGAR
2026-05-054Novo Holdings A/S — 10% ownerConversion (C): 3,327,734 · Purchase (P): 555,555 @ $18 · Conversion (C): 18,000,000 (derivative) @ $0 · Conversion (C): 1,986,369 (derivative) @ $0 · Conversion (C): 25,899,284 (derivative) @ $0 · Conversion (C): 5,587,603 (derivative) @ $0 · +1 moreEDGAR
2026-05-044Golden Adam H. — General CounselGrant/award (A): 254,891 (derivative) @ $0EDGAR
2026-05-014Carroll Jill — DirectorConversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 27,309,719 (derivative) · Conversion (C): 9,418,561 (derivative)EDGAR
2026-05-014SR ONE CAPITAL MANAGEMENT, LLC — 10% owner
George Simeon — 10% owner
Conversion (C): 1,419,298 · Conversion (C): 489,486 · Purchase (P): 277,778 @ $18 · Conversion (C): 354,824 · Conversion (C): 489,486 · Purchase (P): 277,777 @ $18 · +4 moreEDGAR
2026-05-014Congleton Jon — DirectorGrant/award (A): 26,978 (derivative) @ $0EDGAR
2026-05-014Rhodes Melissa — Chief Operating OfficerGrant/award (A): 211,975 (derivative) @ $0EDGAR
2026-05-014Carlson Douglas R — Chief Financial OfficerGrant/award (A): 211,975 (derivative) @ $0EDGAR
2026-05-014Haviland Kate — DirectorGrant/award (A): 26,978 (derivative) @ $0EDGAR
2026-05-014Wellington Biomedical Innovation Master Investors (Cayman) II L.P. — 10% ownerConversion (C): 1,275,486 · Conversion (C): 20,482,289 (derivative) @ $0 · Conversion (C): 4,060,259 (derivative) @ $0EDGAR
2026-05-014Lazarus Howard — Chief Medical OfficerGrant/award (A): 211,975 (derivative) @ $0EDGAR
2026-05-014Lavelle Erin — DirectorGrant/award (A): 26,978 (derivative) @ $0EDGAR
2026-05-014Baranowski Lyn — Chief Executive Officer, DirectorGrant/award (A): 501,033 (derivative) @ $0EDGAR
2026-05-014Turner Heather D — DirectorGrant/award (A): 26,978 (derivative) @ $0EDGAR

Recent 8-K events — Avalyn Pharma Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-168-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersEDGAR
2026-08-128-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-018-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-178-K7.01 — Regulation FD DisclosureEDGAR
2026-06-038-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-018-K5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=AVLN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs